Publications by authors named "V Brescia-Morra"
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, neurodegenerative disease of the central nervous system, significantly impacting patients' quality of life. Understanding patient and healthcare professional (HCP) preferences for MS treatments is crucial for optimizing therapeutic strategies and improving adherence and outcomes. This Discrete-Choice Experiment (DCE) assesses preferences for various MS treatment attributes among Italian patients and HCPs.
View Article and Find Full Text PDFBackground And Purpose: CD20 T lymphocytes are a subset of circulating T cells presenting the CD20 receptor, a molecular marker of B lineage. CD20 T lymphocytes are thought to play a pivotal role in multiple sclerosis (MS) pathology, especially at progressive stages. We aimed to investigate the correlation between CD20 T lymphocytes and neuropsychological features (i.
View Article and Find Full Text PDFObjective: People with multiple sclerosis (MS) might experience symptoms that are usually underestimated. Dysphagia should be evaluated within the Expanded Disability Status Scale (EDSS), but clinicians often do not assess it properly. The objectives of this study are as follows: To assess the prevalence of dysphagia in patients with MS utilizing the Swallowing Disturbance Questionnaire (SDQ); to examine the correlation with the EDSS; to investigate the relationship between dysphagia and clinico-demographic characteristics of MS.
View Article and Find Full Text PDFArticle Synopsis
- The study compares disability progression in Multiple Sclerosis (MS) patients based on age of onset: pediatric (POMS), adult (AOMS), and late-onset (LOMS), as well as those with and without progression independent of relapse activity (PIRA).
- Data from 3,777 MS patients revealed that AOMS showed significant disability increases compared to POMS starting in the second year, with POMS having a less steep disability trajectory over time.
- The findings underscore that younger patients with MS experience different disability progression patterns than older patients, highlighting the importance of age in MS disease management.
Background: Pediatric-onset Multiple Sclerosis (POMS) patients show more inflammatory disease compared with adult-onset MS. However, highly effective treatments are limited with only fingolimod being approved in Italy and natalizumab prescribed as off-label treatment.
Objectives: to compare the efficacy of natalizumab versus fingolimod in POMS.